Sales & Marketing News | pharmaphorum

News

Novo Nordisk's fling with Hims & Hers ends in a bust-up

The alliance between Novo Nordisk and telehealth firm Hims & Hers for the distribution of GLP-1 agonist weight-loss therapies has ended in acrimony.

News

EU kicks off review of GSK's linerixibat in PBC

GSK's drug for severe itching in patients with autoimmune liver disease PBC is now under review in the EU and US, as Mirum Pharma tries to catch up.

News

Madrigal closes on EU approval of first MASH treatment

Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a MASH treatment.

News

Grail plans FDA filing for cancer blood test after new trial

Grail is eyeing FDA approval of its Galleri cancer screening blood test after a second positive phase 3 trial.

News

Dupixent is first FDA-approved drug for rare skin disease

The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.

News

Could a Novo error set up early GLP-1 generics in Canada?

Reports say Novo Nordisk may have inadvertently let generics of its GLP-1 drug semaglutide for diabetes and obesity launch in Canada early next year.

Novo Nordisk's fling with Hims & Hers ends in a bust-up

EU kicks off review of GSK's linerixibat in PBC

Madrigal closes on EU approval of first MASH treatment

Grail plans FDA filing for cancer blood test after new trial

Dupixent is first FDA-approved drug for rare skin disease

Could a Novo error set up early GLP-1 generics in Canada?

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks